Skip Navigation



Hum. Reprod. Advance Access published online on December 16, 2005
Human Reproduction, doi:10.1093/humrep/dei434
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
21/4/1070    most recent
dei434v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Yahata, T.
Right arrow Articles by Tanaka, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yahata, T.
Right arrow Articles by Tanaka, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received July 26, 2005
Revised October 18, 2005
Accepted October 26, 2005

Article

Long-term conservative therapy for endometrial adenocarcinoma in young women

T. Yahata 1 *, K. Fujita 1, Y. Aoki 1, and K. Tanaka 1

1 Department of Obstetrics & Gynecology, School of Medicine, Niigata University, Niigata city, Niigata, Japan

* To whom correspondence should be addressed.
T. Yahata, E-mail: yahatat{at}med.niigata-u.ac.jp


  Abstract

BACKGROUND: To evaluate the efficacy and safety of long-term conservative therapy with medroxyprogesterone acetate (MPA) for endometrial carcinoma in young patients who had experienced failure after initial therapy or relapse, we reviewed the clinical and pathologic records of eight patients diagnosed with well-differentiated endome-trial adenocarcinoma without myometrial invasion who were treated with MPA for over 6 months because of treatment failure or relapse. RESULTS: The average duration of MPA treatment was 22 months. All patients were followed-up for a mean of 76.5 months. Seven patients responded to initial MPA treatment within a period of 14 months (mean, 7.9 months). All these patients experienced relapse and the mean time to relapse was 11.6 months (range, 4-33 months). All six patients with relapse were treated with additional treatments of MPA, and all but one responded to this treatment within a period of 16 months (mean, 8.0 months). Six patients ultimately underwent hysterectomy. All presented well-differentiated endometrioid adenocarcinomas without extrauterine disease. Three became pregnant and two delivered full-term normal infants. No patient died of the disease. CONCLUSION: Although lesions are expected to disappear with prolonged MPA treatment, this form of progestin therapy is hazardous because recurrence occurs frequently. Only strictly selected patients should therefore be indicated for long-term MPA treatment and careful evaluation before and after treatment should be performed.

Keywords: conservative therapy/endometrial adenocarcinoma/medroxyprogesterone acetate.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Wang, P. Hanifi-Moghaddam, E. E. Hanekamp, H. J. Kloosterboer, P. Franken, J. Veldscholte, H. C. van Doorn, P. C. Ewing, J. J. Kim, J. A. Grootegoed, et al.
Progesterone Inhibition of Wnt/{beta}-Catenin Signaling in Normal Endometrium and Endometrial Cancer
Clin. Cancer Res., September 15, 2009; 15(18): 5784 - 5793.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Diagnostic Medical SonographyHome page
T. Boyd
Endometrial Adenocarcinoma
Journal of Diagnostic Medical Sonography, March 1, 2007; 23(2): 106 - 109.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.